Clinical trials: Human Immunodeficiency Virus 1 Positive
HIV Infections
Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)
The purpose of this study is to see if it is effective to add an HIV vaccine (Remune) to the anti-HIV drug combination of Combivir (zidovudine plus lamivudine) and nelfinavir.
- Trial name
- NCT00005002
- Testing
- Lamivudine/Zidovudine, HIV-1 Immunogen, Nelfinavir mesylate
- Where
- United States
- Volunteers
- 688 people
- Sponsor
- Agouron Pharmaceuticals
HIV-1 Infection
A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (behavior in the body) of bevirimat administered for 15 days to HIV-positive individuals.
- Trial name
- NCT01097070
- Testing
- Bevirimat
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- Myrexis Inc.
HIV Infections
Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients
The purpose of this study is to identify an optimal dose combination(s) of tipranavir (TPV) and ritonavir (RTV) for antiretroviral treatment naïve HIV-1 infected patients that can be used in pivotal trial by assessing the…
- Trial name
- NCT00530920
- Testing
- tipranavir, ritonavir
- Where
- 12 sites in Germany, Italy and 1 more
- Volunteers
- 85 people
- Sponsor
- Boehringer Ingelheim
HIV/AIDS
Safety, Tolerability and Immunogenicity of MVA.HTI and ChAdOx1.HTI With Vesatolimod in HIV-1 Positive Patients
AELIX-003 study aims to investigate the safety, tolerability, immunogenicity and efficacy of a regimen containing AELIX Therapeutics' HTI T-cell vaccines and Gilead´s Toll-Like Receptor 7 (TLR7) agonist vesatolimod in…
- Trial name
- AELIX-003 (NCT04364035)
- Testing
- ChAdOx1.HTI, MVA.HTI, GS-9620
- Where
- 9 sites in Spain
- Volunteers
- 50 people
- Sponsor
- Aelix Therapeutics
HIV Infections
A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients
The purpose of this study is to see whether it is better to take delavirdine (DLV) plus indinavir (IDV) plus zidovudine (ZDV) twice a day or three times a day.
- Trial name
- NCT00002236
- Testing
- Indinavir sulfate, Delavirdine mesylate, Zidovudine
- Where
- 6 sites in United States
- Volunteers
- 32 people
- Sponsor
- Pharmacia and Upjohn
HIV Infections
Naïve HIV POC Monotherapy Trial
The primary objective of the trial is: to evaluate the change from baseline in plasma viral load with placebo and one of up to 4 dose regimens of RDEA806.
- Trial name
- NCT00617526
- Testing
- RDEA806 400 mg, RDEA806 1000 mg, RDEA806 600 mg
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 48 people
- Sponsor
- Ardea Biosciences, Inc.
HIV
Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients
The primary objective of the study is to determine the PK (tesamorelin) and PD (IGF-1) profiles of tesamorelin after a single 2 mg subcutaneous administration and after repeated administration once daily for 14 consecutive days.
- Trial name
- NCT02012556
- Testing
- Tesamorelin
- Where
- Canada
- Volunteers
- 18 people
- Sponsor
- Theratechnologies